Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
NEWTON, Mass., Oct. 11, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Executive Vice President, Chief Financial Officer, and Treasurer, will present at the 15th Annual BIO Investor Forum on Tuesday, October 18, 2016 at 11:00 a.m. PT. The conference will be held at the Westin St. Francis in San Francisco.
A live webcast of the event can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,700 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
